Savara (SVRA)
NASDAQ:SVRA
Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.78
$0.04(1.15%)
At close: 4:00 PM EST
$5.78
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.98 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.56M
Market Cap
$1.21B
Enterprise Value$1.09B
Total Cash (Recent Filing)$202.77M
Total Debt (Recent Filing)$30.11M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,844,887
30 Day Avg. Volume1,558,184
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.23K
Enterprise Value/Ebitda-8.46
Forecast
1Y Price Target
$11.17Price Target Upside93.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.18M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModest debt relative to equity gives Savara structural balance-sheet flexibility typical of early-stage biotechs. Lower leverage reduces near-term refinancing pressure, supporting continued clinical investment and preserving optionality for funding R&D over the next several quarters.
Sustained R&D InvestmentOngoing, deliberate investment in R&D signals commitment to advancing the lead inhaled PAP program and other pipeline assets. Sustained clinical spending increases probabilities of near- to medium-term regulatory milestones that could transform revenue prospects for rare pulmonary indications.
Financing & Incentive FlexibilityShare-authority and award-pool expansion provides structural tools to raise capital and retain talent without ad-hoc governance changes. That flexibility can accelerate trial funding and align executive incentives, aiding program execution and organizational stability over the next 2–6 months.
Bears Say
High Cash BurnSubstantial and rising operating cash outflows materially shorten runway and increase the likelihood of near-term financing. Persistent negative free cash flow means the company will likely require external capital, which can pressure strategic choices and ownership dilution over time.
No Revenue; Widening LossesAbsence of product revenue combined with materially increasing net losses undermines internal funding capacity and delays break-even prospects. Continued negative earnings erode equity and limit ability to self-fund pivotal trials, raising execution and capital risk over the medium term.
Heightened Dilution RiskDoubling authorized common shares and enlarging the award pool structurally increases the company's capacity to dilute existing holders when funding or incentivizing management. This raises long-term shareholder dilution risk tied to routine financing or large equity compensation grants.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.98 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.21B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Aug 06, 2026 which is in 38 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.015.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.14.
How many shares outstanding does Savara have?
Savara has 204,927,220 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went up 3.74%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (93.19% Upside)
$11.17 (93.19% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
166.96%
12-Months-Change
Fundamentals
Return on Equity
-87.19%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.17
▲(93.19% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
7.48% Mutual Funds
74.40% Other Institutional Investors
4.72% Public Companies and
Individual Investors